Quick Answer
Passage BIO, Inc. reported Operating Income of -$49.30 million for fiscal year 2025.
Passage BIO, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$49.30M | +30.0% |
| 2024 | -$70.40M | +35.0% |
| 2023 | -$108.39M | +21.7% |
| 2022 | -$138.39M | +25.5% |
| 2021 | -$185.73M | -64.5% |
| 2020 | -$112.90M | -203.6% |
| 2019 | -$37.19M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.65M | +58.2% | +16.2% |
| June 30, 2025 | -$10.33M | +40.5% | +37.2% |
| March 31, 2025 | -$16.46M | +8.8% | +20.5% |
| September 30, 2024 | -$20.70M | +27.8% | -19.1% |
| June 30, 2024 | -$17.38M | +31.6% | +3.7% |
| March 31, 2024 | -$18.05M | +49.7% | +37.0% |
| September 30, 2023 | -$28.67M | -4.2% | -12.9% |
| June 30, 2023 | -$25.39M | +36.2% | +29.2% |
- Passage BIO, Inc. showed an increase of +30.0% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Passage BIO, Inc.’s operating income has declined by 32.6% (from -$37.19 million to -$49.30 million).
- The most recent figure is from Passage BIO, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: